Last update July 30, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Carteolol Hydrochloride in other languages or writings:
Carteolol Hydrochloride belongs to these groups or families:
Main tradenames from several countries containing Carteolol Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 85 | % |
Molecular weight | 329 | daltons |
Protein Binding | 23 - 30 | % |
VD | 4 (2.5 - 7) | l/Kg |
pKa | 13.4 | - |
Tmax | 2 (1 - 3) | hours |
T½ | 3 - 8 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a long-acting cardioselective beta-blocker that is used orally (once a day) in the treatment of hypertension, some arrhythmias and angina pectoris, and, as eye drops (twice a day), to treat glaucoma.
At date of last update were not found published data on its excretion into breast milk.
Its low percentage of plasma protein binding make it likely that it would pass into breast milk in amounts which could be significant (Riant 1986), although its very wide volume of distribution would make it difficult.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
OPHTHALMIC USE:
Following ophthalmic administration of Carteolol 2% for 2 months, peak carteolol plasma concentrations were ≤ 4 ng/mL (nanograms/milliliter). (Bausch 2022, Renard 2005)
Systemic absorption should be minimized by pressing the tear duct (inner corner of the eye) with the finger for 1 to 2 minutes and administering the dose immediately after breastfeeding. (Belkin 2020, Blumen 2020, Méndez 2012)
The small dose and poor plasma absorption of most topical ophthalmological preparations make it unlikely that significant amounts will transfer into breastmilk. Topical use of Carteolol in the form of eye drops is compatible with breastfeeding.